Skip to content
mapperlab
← Dashboard
Stock

WGS

GeneDx Holdings Corp.
Latest close $437 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
7
27 funds tracked
Ever held
7
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Aug 9, 2024Aug 13, 2025Feb 12, 2026May 15, 2026
Now
8

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$33$43+30%
Citadel Advisors$34$43+26%
Two Sigma Investments$34$43+26%
D.E. Shaw re-entered$0.00$43
Millennium Management re-entered$34$43+26%
Point72 Asset Management re-entered$34$43+26%
AQR Capital Management$74$43-42%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at GeneDx Holdings Corp.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
6
Filings · last 90d
14
Total on file
385
Recent SEC buffer
Most recent
Jun 8, 2026

30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 385 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · GeneDx Holdings Corp.

Annual figures sourced directly from GeneDx Holdings Corp.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$427.54M
FY2025+40% YoY
Net income
-$21.02M
FY2025+60% YoY
EPS (diluted)
$-0.7300
FY2025+62% YoY
Free cash flow(?)
$14.26M
FY2025+142% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for GeneDx Holdings Corp. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ2 2026open$41$43+5%
D.E. ShawQ1 2026open$91$43-53%
Renaissance TechnologiesQ1 2026open$91$43-53%
Millennium ManagementQ4 2025open$128$43-67%
D.E. ShawQ4 2024Q4 2025$74$128+74%
AQR Capital ManagementQ4 2024open$74$43-42%
Citadel AdvisorsQ3 2024open$34$43+26%
Two Sigma InvestmentsQ3 2024open$34$43+26%
D.E. ShawQ3 2024open$0.00+0%
Millennium ManagementQ3 2024Q3 2025$34$123+263%
Point72 Asset ManagementQ3 2024Q4 2025$34$128+279%
Renaissance TechnologiesQ3 2024Q3 2025$33$123+276%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.